Quest Diagnostics Reports Impressive Fourth Quarter Results
Quest Diagnostics Incorporated (NYSE: DGX) recently shared its financial accomplishments for the fourth quarter of 2024, showcasing a strong revenue growth of 14.5% compared to the previous year, amounting to $2.62 billion. This significant increase reflects the company's ongoing commitment to enhancing its diagnostic services for patients and healthcare providers.
Financial Overview for Full Year 2024
Throughout 2024, Quest Diagnostics recorded full-year revenues of $9.87 billion, which represented a 6.7% increase from 2023. The company also reported a diluted earnings per share (EPS) of $7.69, a 2.7% rise from the prior year, and an adjusted diluted EPS of $8.93, showcasing a 2.5% growth. This consistency in positive earnings highlights the effective strategies implemented by the management and the innovative approaches introduced across their operations.
Management Commentary on the Future
Jim Davis, Chairman and CEO of Quest Diagnostics, expressed his enthusiasm for the fourth-quarter results, noting, "For the full year, we drove revenue growth of close to 7%, including approximately 3% from organic growth." He emphasized the successful completion of eight acquisitions in 2024, including significant partnerships that enhanced their service offerings and market reach. He highlighted the confidence in their guidance for 2025, reflecting the robust demand for their services and solid operational fundamentals.
Key Highlights from 2024
During the year, Quest Diagnostics made notable achievements aimed at expanding its service capabilities and improving healthcare accessibility. They completed eight acquisitions, enhancing their diagnostic portfolio. The company eagerly collaborated with various health plans, which improved access to diagnostics for over 90% of in-network lives nationwide, further showcasing its commitment to patient care.
New Offerings and Technological Advancements
Quest introduced new testing capabilities through its Advanced Diagnostics portfolio, including p-tau217 and p-tau181 biomarkers for assessing the risk of Alzheimer's disease. Additionally, they launched the first H5 avian influenza test based on a pandemic preparedness contract with the Centers for Disease Control and Prevention (CDC), underscoring their leadership in diagnostic innovation.
Enhanced Patient Services
The company expanded its consumer-initiated test platform, questhealth.com, now offering around 135 different tests. These enhancements enable patients to access vital health information conveniently. Improvements in automation and AI technologies were also deployed across various departments, optimizing service quality and operational efficiency, which translates to better patient experiences.
Dividend Increase
In a show of confidence, Quest Diagnostics' Board of Directors has voted to increase the quarterly dividend by 6.7% from $0.75 to $0.80 per share, signaling a commitment to shareholder returns while investing in future growth. The increase is effective for dividends payable on April 21, 2025, to shareholders of record on April 7, 2025.
Guidance for Full Year 2025
Looking ahead, Quest Diagnostics anticipates that the reported diluted EPS for the full year 2025 will range between $8.34 and $8.59. Expectations for adjusted diluted EPS are higher, projected between $9.55 and $9.80. This outlook mirrors the company's lasting focus on delivering value and growth for its stakeholders.
Frequently Asked Questions
What is the reported revenue growth for Quest Diagnostics in 2024?
Quest Diagnostics reported a revenue growth of 14.5% in the fourth quarter of 2024, reaching $2.62 billion.
How much did the company increase its dividend in 2025?
The quarterly dividend was increased by 6.7%, from $0.75 to $0.80 per share.
What are the projected EPS figures for Quest Diagnostics in 2025?
For the full year 2025, the reported diluted EPS is expected to be between $8.34 and $8.59.
What new services did Quest Diagnostics introduce in 2024?
They introduced advanced testing services, including biomarkers for Alzheimer's disease and a new avian influenza test.
How does Quest Diagnostics support healthcare access?
The company extended health plan access to over 90% of in-network lives nationwide, partnering with various health organizations.
